Rationalizing Pharmaceutical Spending /

Pharmaceutical spending accounts for a large share of health spending worldwide. While pharmaceuticals are an indispensable component of effective modern health systems, and their benefits in terms of increasing life expectancy and improving quality of life are unquestionable, the large variation in...

Popoln opis

Bibliografske podrobnosti
Glavni avtor: Garcia-Goni, Manuel
Format: Revija
Jezik:English
Izdano: Washington, D.C. : International Monetary Fund, 2022.
Serija:IMF Working Papers; Working Paper ; No. 2022/190
Teme:
Online dostop:Full text available on IMF
LEADER 02175cas a2200301 a 4500
001 AALejournalIMF023217
008 230101c9999 xx r poo 0 0eng d
020 |a 9798400219849 
020 |c 20.00 USD 
022 |a 1018-5941 
040 |a BD-DhAAL  |c BD-DhAAL 
100 1 |a Garcia-Goni, Manuel. 
245 1 0 |a Rationalizing Pharmaceutical Spending /  |c Manuel Garcia-Goni. 
264 1 |a Washington, D.C. :  |b International Monetary Fund,  |c 2022. 
300 |a 1 online resource (48 pages) 
490 1 |a IMF Working Papers 
500 |a <strong>Off-Campus Access:</strong> No User ID or Password Required 
500 |a <strong>On-Campus Access:</strong> No User ID or Password Required 
506 |a Electronic access restricted to authorized BRAC University faculty, staff and students 
520 3 |a Pharmaceutical spending accounts for a large share of health spending worldwide. While pharmaceuticals are an indispensable component of effective modern health systems, and their benefits in terms of increasing life expectancy and improving quality of life are unquestionable, the large variation in pharmaceutical spending across countries suggests that there may be large efficiency gains to be realized. This paper reviews the existing literature and databases on the level and composition of pharmaceutical spending and estimates potential efficiency gains from increased use of generics. It also reviews how countries organize the procurement and tendering of pharmaceuticals and the implications for spending. Finally, the paper identifies the various channels through which spending inefficiencies can arise and identifies reform options for reducing pharmaceutical spending while ensuring quality health outcomes. 
538 |a Mode of access: Internet 
650 7 |a Generics  |2 imf 
650 7 |a Health  |2 imf 
650 7 |a National Government Expenditures and Related Policies  |2 imf 
650 7 |a Pharmaceutical Policy  |2 imf 
650 7 |a Pharmaceutical Spending  |2 imf 
830 0 |a IMF Working Papers; Working Paper ;  |v No. 2022/190 
856 4 0 |z Full text available on IMF  |u https://elibrary.imf.org/openurl?genre=journal&issn=1018-5941&volume=2022&issue=190  |z IMF e-Library